Floatz logo

Favezelimab

Neoplasms

Merck Sharp & Dohme LLCmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
65/ 100

Competitive context

927 Active assets in the Neoplasms cohort.

Asset / SponsorPhaseRating
PANITUMUMAB
Astellas Pharma Inc
Phase 2BBB
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM
Sanofi
Phase 4BB
Bxcl501
Medical College of Wisconsin
Phase 4BB
LIDOCAINE
Medical College of Wisconsin
Phase 4BB
Glycopyrrolate
Medical College of Wisconsin
Phase 4BB

View all 50 →

Same molecule, other indications

Favezelimab is also rated in:

Hodgkins lymphomaDormant
BB
Indicative ·
67 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
60 / 100
View asset →
skin squamous cell carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →